Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Long-Term Investments (2022 - 2023)

Gain Therapeutics has reported Long-Term Investments over the past 2 years, most recently at $988388.0 for Q1 2023.

  • Quarterly results put Long-Term Investments at $988388.0 for Q1 2023, changed N/A from a year ago — trailing twelve months through Mar 2023 was $988388.0 (changed N/A YoY), and the annual figure for FY2022 was $1.9 million, changed.
  • Long-Term Investments for Q1 2023 was $988388.0 at Gain Therapeutics, down from $1.9 million in the prior quarter.
  • Over the last five years, Long-Term Investments for GANX hit a ceiling of $4.9 million in Q2 2022 and a floor of $988388.0 in Q1 2023.